MedTrace Logo

Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation

NCT05523336 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-05-25

No results posted yet for this study

Summary

Prospective, multicenter, spontaneous, non-interventional, non pharmacological. Study aimed at evaluate kinetics, diagnostic and prognostic value of pro-ADM (proadrenomedullin) as compared to PCT (procalcitonin) in patients presenting with infections or other complications post hematopoietic stem cell transplantation (HSCT)

Conditions

  • Stem Cell Transplant Complications

Interventions

OTHER

observation

observation and prospective data collection

Sponsors & Collaborators

  • Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

    lead OTHER

Principal Investigators

  • Franca Fagioli, MD · AOU Città della Salute e della Scienza di Torino - OIRM

  • Manuela Spadea, MD · AOU Città della Salute e della Scienza di Torino - OIRM

Eligibility

Min Age
28 Days
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2024-09-30
Completion
2025-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523336 on ClinicalTrials.gov